That one subtle change made a striking difference. After three doses, 80% of volunteers who received a membrane-bound version produced \u201ctier 2\u201d neutralizing antibodies. This is a benchmark that suggests good protection against the virus. Meanwhile, in the group that received the traditional soluble form, only 4% did.<\/p>\n
\u201cThe difference is pretty striking,\u201d Sharon Lewin, head of the Peter Doherty Institute for Infection and Immunity, who was not involved in the research, told Nature<\/a>. \u201cThese are the first studies, so they\u2019re very, very important.\u201d<\/p>\n Why is an HIV vaccine so hard to make<\/p>\n Since its discovery in 1983, HIV has proven uniquely slippery. The virus wears a dense coat of sugars, shielding key targets from antibodies, and mutates so rapidly that even an immune system<\/a> that manages to block one strain is often powerless against the next.<\/p>\n For decades, most vaccine candidates have targeted the \u201cenvelope trimer\u201d\u2014a three-pronged protein that HIV uses to latch onto immune cells. In reality, much of the trimer\u2019s base is hidden against the viral membrane. Soluble protein vaccines, however, expose that base. This, in turn, prompts the body to make antibodies that bind there. But these antibodies can\u2019t stop the actual infection.<\/p>\n The new approach, developed by William Schief and colleagues at Scripps Research and Moderna, anchors the protein to cell membranes. That way, the immune system learns to recognize more vulnerable, real-world parts of the virus and can effectively eliminate the virus<\/p>\n Over 100 HIV vaccine trials have been undertaken over the years. But this one seemed particularly promising.<\/p>\n Animal tests<\/a> hinted that such vaccines might work better. The new trial, involving humans, confirmed it.<\/p>\n What the Trial Found<\/p>\n The study enrolled 108 healthy adults aged 18 to 55. Participants were randomly assigned to one of three vaccines: the soluble trimer, a membrane-bound trimer, or a membrane-bound version with a mutation to block CD4 receptor binding. Each group received either a low (100 \u03bcg) or high (250 \u03bcg) dose, three times over six months.<\/p>\n Tests on volunteers\u2019 blood showed that the membrane-bound vaccines spurred a stronger immune reaction than the traditional approach. They also seemed to \u201ctrain\u201d the immune system to focus less on parts of the virus that don\u2019t help much in stopping infection, and more on its weak spots\u2014regions known as V1\/V3 and C3\/V5\u2014that are more likely to block HIV.<\/p>\n These vaccines also built up a stockpile of memory B cells, which act like long-term sentries, and activated specialized T cells, which help coordinate the body\u2019s entire immune defense. The entire body\u2019s immune system mobilized for the task.<\/p>\n But there were limits. The antibodies produced were \u201cautologous.\u201d They recognized the particular virus strain the vaccine had, but not the many other HIV strains circulating worldwide. The ultimate goal is to elicit broadly neutralizing antibodies<\/a> (bnAbs), which can target conserved sites across diverse strains.<\/p>\n The side effects were significant, but not truly threatening.<\/p>\n Seven participants \u2014 about 6.5 percent \u2014 developed hives, or urticaria, after vaccination. In five cases, the condition became chronic, lasting more than six weeks; in some, symptoms persisted for years. The reaction occurred across all three vaccine types, at both doses, and has not been seen in mRNA vaccines<\/a> against other viruses.<\/p>\n![\"An](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/08\/HIV_Vaccine_Awareness-1024x682.jpg\")
<\/a>An HIV general vaccine is still some years away, but scientist just took a huge leap. Credit: NIAID\/Wikimedia Commons<\/p>\n![\"Scanning](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/08\/HIV-budding-Color-1024x680.jpg\")
<\/a>Scanning electron micrograph of HIV-1 budding (in green) from a cultured lymphocyte. Credit: Wikimedia Commons<\/p>\n